How much funding has CorMedix raised?

CorMedix has raised $150.0M in total funding, most recently a Convertible Note round.

Who are CorMedix's investors?

CorMedix's investors include Deerfield Management.

Where is CorMedix headquartered?

CorMedix is headquartered in Berkeley Heights, New Jersey, United States.

What industry is CorMedix in?

CorMedix operates in Biotech, Healthcare, pharmaceuticals.

CorMedix

IPO

Home - CorMedix | Prevention of cardiac, renal and infectious diseases

Public · Berkeley Heights, United States · Founded 2006 · $150.0M raised

Biotech

Healthcare

pharmaceuticals

Headquarters: Berkeley Heights, New Jersey
Founded: 2006
Business Model: B2B
Website: cormedix.com

Total Funding: $150.0M
Last Round: $150.0M Convertible NoteAug 2025
Rounds: 1
Type: Public

About

CorMedix (now CorMedix Therapeutics, NASDAQ: CRMD) is a biopharmaceutical company founded in 2006 and headquartered in Berkeley Heights, New Jersey. The company focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, including its lead product DefenCath (taurolidine/heparin), an FDA-approved catheter lock solution. In 2025, CorMedix acquired Melinta Therapeutics, significantly expanding its commercial antibiotic portfolio.

Summary

CorMedix is a Biotech company based in Berkeley Heights, United States, founded in 2006. It has raised $150.0M in total across 1 round, most recently a $150.0M Convertible Note round in Aug 2025. Investors include Deerfield Management.